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Abstract
Background: Experimental models are important to the understanding of the pathophysiology of, as well as the
effects of therapy on, certain diseases. In the case of chronic kidney disease-mineral bone disorder, there are currently
two models that are used in evaluating the disease: 5/6 nephrectomy (Nx) and adenine-induced renal failure (AIRF).
However, the two models have never been compared in studies using animals maintained under similar conditions.
Therefore, we compared these two models, focusing on the biochemical, bone histomorphometry, and vascular
calcification aspects.
Methods: Wistar rats, initially fed identical diets, were divided into two groups: those undergoing 5/6 Nx (5/6Nx group)
and those that were switched to an adenine-enriched diet (AIRF group). After 9 weeks, animals were sacrificed, and we
conducted biochemical and bone histomorphometry analyses, as well as assessing vascular calcification.
Results: At sacrifice, the mean body weight was higher in the 5/6Nx group than in the AIRF group, as was the mean
blood pressure. No differences were seen regarding serum phosphate, ionized calcium, intact parathyroid hormone
(PTH), or fibroblast growth factor 23 (FGF23). However, creatinine clearance was lower and fractional excretion of
phosphate (FeP) was higher in the AIRF group rats, which also had a more severe form of high-turnover bone disease.
Vascular calcification, as evaluated through von Kossa staining, was not observed in any of the animals.
Conclusions: Overt vascular calcification was not seen in either model as applied in this study. Under similar conditions
of diet and housing, the AIRF model produces a more severe form of bone disease than does 5/6 Nx. This should be
taken into account when the choice is made between these models for use in preclinical studies.
Keywords: Bone disease, Chronic kidney disease, Hyperparathyroidism, Phosphate binder, Vascular calcification
Background
Chronic kidney disease (CKD) is a worldwide health
problem, commonly associated with high morbidity and
mortality. One common and challenging complication is
CKD-mineral bone disorder (CKD-MBD), defined by ab-
normalities in mineral and hormone metabolism, as well
as bone histological changes, with or without soft tissue
calcification [1]. However, many pathophysiological as-
pects of CKD-MBD are still not completely understood.
As a result, new therapeutic strategies, although needed,
are scarce. In addition, clinical trials that could improve
our understanding of CKD-MBD and the potential bene-
fits or hazards of therapeutic interventions are extremely
difficult and costly to conduct. In this regard, animal
models could be a strategic option, providing the oppor-
tunity to examine the basic aspects of this disease, and
its treatment.
Until recently, 5/6 nephrectomy (Nx), first described
at the beginning of the 20th century [2], was the most
common animal model used in preclinical studies evalu-
ating CKD-MBD. However, the 5/6Nx model has several
drawbacks: it requires surgical skill; it has a high mortality
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rate; and pronounced MBD takes several weeks to develop
[3]. During the last few years, a model originally suggested
in the 1980s [4], based on the nephrotoxicity provoked by
adenine, has been also employed in this setting. In that
model, CKD is induced by administration of adenine in
diet or solution, thereby precluding the need for surgery.
Authors who have employed the adenine model to evaluate
CKD-MBD have reported that it provokes a more severe
form of the disease, with impressive bone alterations, as
well as significant VC [5,6]. Nevertheless, it is difficult to
compare the results obtained with these two models, be-
cause the dietary protocol employed has not been stan-
dardized (neither in terms of the amount and duration of
adenine administration, nor in terms of the dietary con-
centrations of calcium, phosphate, and protein), as well
as because the observation period and therapeutic strat-
egies have varied across studies. Therefore, the exact dif-
ferences between the 5/6Nx and adenine models, as well
as which would be the best model to evaluate a specific
aspect of bone disease, remain unclear. To answer these
questions, we decided to compare both models under
identical conditions, in terms of animal species, diet, and
duration of CKD.
Methods
Ethics statement
All experimental procedures were approved by and con-
ducted in accordance with the guidelines of the Standing
Committee on Animal Research of the Universidade de
São Paulo School of Medicine (Protocol no. 0447/08).
Experimental protocol
Thirty five male Wistar rats, weighing 300–350 g,
were obtained from our local breeding colony. They
were housed in individual cages in a temperature- and
humidity-controlled environment (25°C at 25% humidity),
on a 12/12-h light/dark cycle, and fed a standard powder
diet containing 1.17% calcium, 0.93% phosphate, 19.3%
protein, and 4.2 IU/g vitamin D3 (LabDiet® 5C3Y; PMI
Nutrition International, St. Louis, MO, USA), with ad
libitum access to water. After 1 week of acclimatization,
rats were allocated to be submitted to 5/6Nx, which
consisted of removal of the right kidney and infarction
of approximately 2/3 of the left kidney, or to start an
adenine-enriched diet (LabDiet® 5 K52 plus 0.75% and
0.50% adenine; PMI Nutrition International). A normal
renal function Control group was also allocated. The
Control and the 5/6Nx groups rats were fed the standard
diet throughout the study. For the AIRF group, the aden-
ine concentration was 0.75% in the first two weeks and
0.50% in the following two weeks. Thereafter, the AIRF
group rats were fed the standard diet [7]. A pair-feeding
protocol was used. On a weekly basis, the rats were
weighed and blood pressure was measured by tail cuff
plethysmography. At 9 weeks after the surgical procedure
and the start of adenine administration, rats were anes-
thetized and sacrificed by exsanguination via aortic
puncture.
We injected each rat intraperitoneally with 25 mg/kg
oxytetracycline (Terramycin®; Pfizer Animal Health, New
York, NY, USA), a fluorescent marker of bone, on days
51, 52, 58 and 59 of the protocol, for dynamic evaluation
of bone histomorphometry. We also collected 24-h urine
samples, 1 day before the sacrifice, in order to quantify
urine output and perform biochemical analysis.
Serum samples were collected at the time of sacrifice
by aortic puncture and stored at −20° for subsequent
biochemical evaluation. The heart was excised, and the
left ventricle was dissected for weighing and determin-
ation of the left ventricle weight normalized to body
weight (LVW/BW). Thoracic and abdominal aortas were
removed in order to evaluate VC, by von Kossa staining
and calcium content quantification, respectively. Femurs
were removed for bone histomorphometry.
Biochemical analysis
In serum samples, we measured creatinine and phos-
phate by colorimetric assay (Labtest, Lagoa Santa, Brazil);
ionized calcium was measured with an ion-selective
analyzer (AVL-9140; AVL Scientific Corporation, Roswell,
GA, USA); the PTH level was determined by enzyme-
linked immunosorbent assay (ELISA kit; Immutopics, San
Clemente, CA, USA), as was the level of FGF23 (ELISA
kit; Kainos Laboratories, Tokyo, Japan); calcitriol was quan-
tified by radioimmunoassay using a pool of samples. In
urine samples, we quantified creatinine, phosphate, and
calcium by colorimetric assay (Cobas Amplicor; Roche
Diagnostics, Indianapolis, IN, USA).
Bone histomorphometry
The left femur of each rat was removed, dissected free of
soft tissue, immersed in 70% ethanol, and processed as
previously described [8]. Using a Jung K microtome
(Reichert Jung, Heidelberg, West Germany), we cut dis-
tal femurs into sections of 5 μm and 10 μm thickness.
The 5-μm sections were stained with 0.1% toluidine
blue, pH 6.4, and we examined at least two nonconsecu-
tive sections per sample.
Structural, static, and dynamic parameters of bone
formation and resorption were measured at the distal
metaphysis (magnification, ×250), at 195 μm from the
epiphyseal growth plate, in a total of 30 fields, using a
semi-automatic image analyzer (Osteomeasure; Osteo-
metrics, Atlanta, GA, USA). Structural parameters in-
cluded trabecular thickness (in μm), trabecular separation
(in μm), and trabecular number (in trabeculae/mm). The
indices of static formation included the proportions of tra-
becular bone volume and osteoid volume to total bone
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volume (both in %); osteoid thickness (in μm); and
osteoid/osteoblast surfaces (both in % of bone surface).
The indices of static resorption included eroded surface
and osteoclast surface (both in % of bone surface). The
mineral apposition rate, determined by measuring the
distance between the two oxytetracycline labels and div-
iding it by the time elapsed between the two oxytetra-
cycline administrations, is expressed in micrometers per
day. Mineralization lag time is expressed in days. Deter-
mination of the proportion of double oxytetracycline-
labeled surface to total trabecular surface (in %) and of the
bone formation rate completed the dynamic evaluation.
Results are also described according to the turnover-
mineralization-volume (TMV) classification [9]. Histo-
morphometric indices were reported using nomenclature
recommended by the American Society of Bone and
Mineral Research [10].
Vascular calcification
Cross-sections of the thoracic aorta were embedded in
paraffin, sectioned at 4 μm, and stained with von Kossa.
For the analysis of calcium concentration, the abdominal
aorta was solubilized in 0.6 N HCl (40 μL HCl/g tissue)
for 48 h, after which it was dried and weighed. The
sample was then centrifuged, and the calcium content was
measured in the supernatant (Calcium Reagent Set; Pointe
Scientific, Canton, MI, USA).
Statistical analysis
Results are presented as mean ± SD or median (min-max).
Comparisons among groups were made using Anova.
Graph Pad Prism version 3.03 (GraphPad Software, Inc.,
San Diego, CA, USA) were used. Values with P < 0.05 were
considered as statistically significant.
Results
Study sample
The final study sample comprised 30 rats: 10 in the
5/6Nx group; 10 in AIRF group; and, 10 in Control
group. Although 15 rats were submitted to 5/6 Nx, three
died (on post-procedure days 3, 7, and 50, respectively)
and two others were excluded from the final analysis be-
cause of the severity of renal failure (serum creatinine
levels of 6.7 and 3.5 mg/dl, respectively). There were no
deaths in the AIRF group. As shown in Table 1, despite
the use of a pair-feeding protocol, the mean body weight
at sacrifice was lower in the AIRF group. Mean urine out-
put was significantly higher in the AIRF group, whereas
mean blood pressure was higher in the 5/6Nx group. No
differences were seen regarding the LVW/BW.
Biochemical parameters
Creatinine levels tended to be higher in the AIRF group
than in the 5/6Nx group, whereas a significant difference
regarding creatinine clearance was seen between uremic
groups (Table 2). The two groups were comparable in
terms ionized calcium, phosphate, PTH, and FGF23.
However, despite the similar serum phosphate levels,
FeP was higher in the AIRF group. In addition, calcitriol
levels were significantly lower in the 5/6Nx group.
Bone histomorphometry
Bone histomorphometry revealed that the bone forma-
tion rate was significantly higher in the AIRF group rats
than in the 5/6Nx group rats. Other parameters of bone
formation, such as osteoid and osteoblast surfaces, as
well as resorption and osteoclast surfaces, were also sig-
nificantly higher in the AIRF group. The mineralization
lag time was higher in AIRF group. We also observed no
significant differences between the two groups in terms of
trabecular bone volume. However, bone microarchitecture
was altered in the AIRF group animals, as evidenced by a
lower trabecular number and greater trabecular separation.
Fibrosis was observed in only one AIRF rat (Table 3).
Table 1 Characteristics of the rats evaluated1
Variable Control AIRF 5/6Nx
(n = 10) (n = 10) (n = 10)
Initial body weight (g) 324.4 ± 37.4 307.1 ± 30.8 307.9 ± 19.9
Final body weight (g) 366.1 ± 18.7 312.0 ± 17.2a 385.4 ± 59.8a,b
Food intake (g/day) 17.5 ± 1.4 16.8 ± 1.9 18.9 ± 0.7b
Urine output (ml) 11.4 ± 5.4 53.7 ± 11.2a 22.7 ± 6.7a,b
TCP-BP (mmHg) 119.7 ± 7.3 154.4 ± 20.4a 220.0 ± 19.5a,b
LVW/100 g BW 0.18 ± 0.01 0.21 ± 0.02a 0.21 ± 0.05
1Data expressed as mean ± SD.
TCP-BP, Blood pressure, as measured by tail cuff plethysmography.
Initial, Before Nx5/6 and adenine diet protocol.
Final, At the sacrifice.
ap < 0.05 vs. Control; bp < 0.05 vs. AIRF.
Table 2 Biochemical data at the sacrifice
Variable Control (n = 10) AIRF (n = 10) 5/6Nx (n = 10)
Serum Cr (mg/dl) 0.6 ± 0.1 1.6 ± 0.3a 1.3 ± 0.6a
Creat Clear (ml/min) 2.55 ± 0.74 0.67 ± 0.25a 1.1 ± 0.46a,b
Serum iCa (mmol/L) 1.2 ± 0.1 1.1 ± 0.1 1.1 ± 0.1
uCa (mg/dl) 14 (8–17) 6 (4–8) 11 (5–50)
Serum P (mg/dl) 5.6 ± 0.9 7.4 ± 0.7a 6.7 ± 1.4
FeP (%) 9.1 ± 4.8 21.2 ± 11.0a 7.6 ± 4.6b
iPTH (pg/ml) 108 (47–315) 681 (163–1,604)a 572 (198–4,199)a
FGF23 (pg/ml) 157 (107–310) 784 (418–14.476)a 893 (649–2.609)a
Calcitriol (pg/ml)* 69.2 ± 17.3 88.0 ± 16.6 35.1 ± 20.0b
Data expressed as mean ± SD or median (min-max).
Creat Clear, Creatinine clearance; Serum iCa, Serum ionized calcium; uCa,
Urinary calcium; Serum P, Serum phosphate. *Calcitriol was measured in
pooled sera.
P < 0.05 avs Control; bvs AIRF.
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Vascular calcification
Von Kossa staining was negative in both groups. How-
ever, calcium content in the abdominal aorta was signifi-
cantly greater in the 5/6Nx group (Table 4).
Discussion
To our knowledge, this was the first study to compare,
under similar conditions, the most widely used animal
models of CKD-MBD. We showed that, in rats fed iden-
tical diets and observed for the same length of time,
renal dysfunction and bone disease are more severe
when the AIRF model is employed.
Initially described in 1932, 5/6Nx (ligation of the renal
artery branches, electrocauterization of the renal cortex
or removal of the left kidney poles and right kidney
nephrectomy) reduces the effective mass of the kidneys
[11]. The effectiveness of this model is dependent upon
the anatomy of individual animals and the experience of
the researcher, leading to different levels of CKD [12].
According to classical descriptions, animals submitted to
5/6Nx develop hyperphosphatemia, reduced calcitriol
levels, and hyperparathyroidism, as well as VC and high-
turnover bone disease [3,13-15]. VC is typically seen at
approximately 12 weeks after the surgical procedure un-
less the animals are fed with a high-phosphate diet or
calcitriol is administered to them [16]. Of the 15 rats ini-
tially included in our 5/6Nx group, three died. This
could be attributed to the surgical procedure itself or to
greater renal disease severity. Given that two additional
animals were excluded from the final analysis because
they had extremely high serum creatinine levels, it is
clear that, when the 5/6Nx model is employed, such
losses must be taken into account and a higher number
of rats should be included in the original sample. Con-
sidering the potential expenses involved, this could be
viewed as a disadvantage of the 5/6 Nx model in com-
parison with the AIRF model.
The adenine model of nephrotoxicity was first de-
scribed in 1982, when Yokozawa et al. observed that
2.8-dihydroxyadenine, a metabolite of adenine, precipi-
tated as crystals in renal tubules, causing rats fed an
adenine-rich diet to develop uremia [4]. Since then,
adenine-enriched diets or solutions of adenine, in various
concentrations, have been used by many authors for
varying periods of time and for different purposes. In
2003, Katsumata et al. used this model, feeding rats a
0.75% adenine diet for 3 weeks in order to study the ef-
fects of sevelamer [5]. In 2006, Tamagaki et al. analyzed
the bone and metabolic characteristics of AIRF in rats
after 2, 4, and 6 weeks on a 0.75% adenine diet and
showed that VC develops only after 4 weeks, whereas in-
cipient bone disease was seen at 2 weeks, leading to a se-
vere skeletal impairment after 6 weeks [6]. In that same
year, Nagano et al. published the results of an experiment
involving a different dose of adenine (0.75% for 2 weeks
followed by 0.50% for 2 weeks) and showed that the
rats developed renal failure, as well as hyperphosphate-
mia, secondary hyperparathyroidism, and reduced calci-
triol levels [7]. Subsequent studies involved different
adenine concentrations and periods of administration
[5-7,12,14,17,18]. So, it seems clear that the degree of
renal dysfunction, as well as the extent of bone disease
and VC, is totally dependent on the amount of adenine
administered and the duration of administration.
One important element in the construction of an ex-
perimental model of CKD is the amount of calcium and
phosphate administered in the diet, as well as the source
of phosphate (grain or casein). The bioavailability of
phosphate is greater for diets based on casein (cow-milk
protein) than for those based on grain [19]. In addition,
the phosphate load should be quantified by measuring
the FeP, given that serum phosphate might not increase
if parathyroid function is preserved since PTH increases
Table 3 Bone histomorphometry data
Parameter Control AIRF 5/6Nx
(n = 10) (n = 10) (n = 10)
BV/TV (%) 25.0 ± 4.8 31.1 ± 6.7 30.3 ± 3.7
TbN (n/mm) 3.7 ± 0.6 3.3 ± 0.7 4.7 ± 0.5a,b
Tb.SP (μm) 208.8 ± 48.2 223.6 ± 95.6 147.6 ± 26.5b
Tb.Th (μm) 67.1 ± 5.5 93.4 ± 8.8a 63.8 ± 4.0b
ObS/BS (%) 5.4 ± 3.0 25.3 ± 6.2a 5.8 ± 2.3b
OV/BV (%) 0.45(0.14-0.56) 1.46(0.54-3.78)a 0.28(0.20-0.77)b
O.Th (μm) 1.7 ± 0.4 2.6 ± 1.3 1.5 ± 0.2b
OS/BS (%) 1.6(1.2-2.1) 30.3(18.8-40.5)a 6.1(5.1-13.9)b
OcS/BS (%) 1.9 ± 1.1 7.4 ± 2.8a 3.2 ± 1.5b
ES/BS (%) 9.1 ± 1.9 24.5 ± 6.3a 12.3 ± 5.1b
MS/BS (%) 6.0(3.7-9.1) 10.3(7.1-14.3) 2.4(0.8-5.3)a,b
MAR (μm/day) 0.8 ± 0.4 1.0 ± 0.7 0.8 ± 0.2b
BFR (μm3 /μm2 per day) 0.03(0.01-0.05) 0.14(0.01-0.22) 0.02(0.01-0.03)b
MLT (d) 3.6(1.6-8.1) 8.4(1.4-136.0)a 4.6(3.4-14.8)b
Data expressed as mean ± SD or median (min-max).
BV/TV, Bone volume/trabecular volume; TbN, Trabecular number; Tb.SP,
Trabecular separation; TbTh, Trabecular thickness; Obs/BS, Osteoblast surface/
bone surface; OV/BV, Osteoid volume/bone volume; O.Th, Osteoid thickness;
OS/BS, Osteoid surface/bone surface; OcS/BS, Osteoclast surface/bone surface;
ES/BS, Eroded surface/bone surface; MS/BS, Mineralization surface/bone surface;
MAR, Mineral apposition rate; BFR, Bone formation rate; MLT, Mineralization
lag time.
ap < 0.05 vs. Control; bvs. AIRF.
Table 4 Vascular calcification
Parameter Control AIRF 5/6Nx
AAC (μmol/mg) 9.6 (8.6-10.6) 7.0 (4.7-11.4) 15.1(13.3-17.9)a,b
Data expressed as median (min-max).
AAC, Abdominal aortic calcium.
ap < 0.05 vs. Control; bvs. AIRF.
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renal phosphate excretion. Therefore, in the present
study, we designed an experiment in which we tested
the 5/6Nx and AIRF under identical conditions in terms
of the calcium, phosphate (from grain), and protein con-
tent of the diet.
We found that the AIRF group rats had lower weight,
despite the pair-feeding protocol, as has been reported
previously [6]. This has been attributed to the poor pal-
atability of adenine, as well as to the uremia and polyuria
caused by tubular disease, which in addition to the in-
gestion of a minimal amount of water, could lead to de-
hydration and weight loss [20]. This finding should be
interpreted as a limitation of AIRF.
The 5/6Nx model induces a progressive glomerular
sclerosis, whereas the adenine model promotes intratub-
ular crystal precipitation and interstitial nephritis. Based
on this, we would expect to find proteinuria, hyperten-
sion and cardiac hypertrophy in the first model, whereas
acidosis and more severe bone lesions would be seen in
the second model. In our experiment, the LVW/BW was
similar between the two groups, despite the higher blood
pressure observed in the 5/6Nx group. This was prob-
ably because the AIRF group rats showed greater uremia,
which is also a risk factor for ventricular hypertrophy
(in fact, we found a positive correlation between serum
creatinine and LVW/BW; R = 0.69, p < 0.05). Therefore,
the 5/6Nx model is indicated for studies evaluating
ventricular hypertrophy associated with hypertension,
whereas the adenine model would be more appropriate for
the study of other variables that could lead to ventricular
hypertrophy.
We found the two groups to be comparable in terms
of serum and urinary calcium, as well as serum phos-
phate. However, FeP was found to be significantly higher
in the AIRF group, which could be explained by the
increased bone turnover or by tubulointerstitial ne-
phropathy, with direct tubular damage leading to phos-
phaturia. In favor of the latter theory, we found no
statistically significant correlation between FeP and the
two major phosphaturic hormones, PTH and FGF23,
nor between FeP and bone resorption parameters (data
not shown). However, a direct effect of adenine on the
tubular excretion of phosphate has never been shown.
Our data also show that there were no significant differ-
ences between the two models in terms of PTH or
FGF23. Various authors have reported an extreme in-
crease in PTH levels in the adenine model. However,
some [6] administered adenine for a longer period time,
whereas others measured PTH using assays that were
different from ours, impeding comparisons across studies.
In addition, as previously mentioned, none of the previous
studies compared the adenine model to 5/6Nx model in a
single experiment. Surprisingly, we found higher calci-
triol levels in AIRF than in Nx group. However, calcitriol
levels in AIRF were not different from Control group,
results that are similar to those were described by
Damment et. al, who found no significant differences
in calcitriol levels between normal renal function and
chronic renal failure, adenine-treated rats [17]. The rea-
sons for this unexpected finding could be the combin-
ation of non-significant higher PTH levels and lower
FGF-23 in adenine-treated rats or a technical issue with
calcitriol measurements, which are usually done in pools
of sera, due to the significant amount of serum that is ne-
cessary for this procedure or even an increased calcitriol
synthesis in the interstitial renal granulomas that are usu-
ally seen around adenine crystals [21].
The bone effects of 5/6Nx and AIRF are distinct, con-
firming previous findings that the natural history of
CKD-MBD could be also dependent on the model that
was chosen to perform the experiments [22,23]. In our
study, we found a high-turnover bone disease in AIRF.
Notable among our histomorphometric findings are the
bone formation rate and the proportion of osteoid sur-
face, which were 5 times higher in the AIRF group rats
than in the 5/6Nx group rats. We also found a positive
correlation between serum creatinine and bone forma-
tion rate (R = 0.59; p < 0.05), showing that worse renal
function leads to higher bone turnover. Nevertheless, os-
teoblasts were apparently unable to increase bone matrix
deposition to the same degree, probably because this
process is not only cell-mediated but also physicochemi-
cal, as AIRF caused greater phosphate loss in urine,
probably impairing mineralization. In addition, accumu-
lating evidence suggests that extracellular nucleotides,
signaling through P2 purinoceptors, play an important
role in modulating bone cell function. Adenosine tri-
phosphate and other nucleotides can stimulate the for-
mation and resorptive activity of osteoclasts, as well as
inhibiting bone mineralization by osteoblasts [24]. Be-
cause adenosine is derived from adenine, a purine base,
we cannot rule out the hypothesis that high doses of ad-
enine lead to an increase in adenosine, which might have
direct effects on the function of osteoblasts and osteo-
clasts. However, we did not observe any crystal in bone
marrow in our samples. Another possibility is that the
lower calcitriol levels described in some adenine animal
studies could be responsible for the observed increase in
osteoid parameters; however, in the present study, calci-
triol levels were significantly higher in the AIRF group
than in the 5/6Nx group. Although metabolic acidosis
could also influence bone findings in the adenine model,
we did not measure whole blood pH, which could be
viewed as a limitation of our study. However, a recent
study employing the adenine model, in which serum cre-
atinine at the end of the study was similar to that described
in our experiment, showed levels of pH and CO2 that
could not explain the magnitude of the bone findings,
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making it less probable that metabolic acidosis is a relevant
factor [17]. Nevertheless, despite the fact that the cause of
the increased amount of osteoid observed in the adenine
model remains unknown, this finding should be kept in
mind when choosing a model to evaluate the bone effects
of certain drugs, such as phosphate binders. The adminis-
tration of these drugs in the adenine model of CKD
could increase osteoid parameters, as previously shown
by Neven et al. [18].
We found it surprising that the von Kossa staining
was negative in both groups and that the calcium con-
centration in the abdominal aorta was higher in the
5/6Nx group. This would seem to be in disagreement
with the current concept that the AIRF frequently leads
to VC. However, our animals received less adenine than
did those described in the study conducted by Tamagaki
et al. [6], which treated animals for 6 weeks with 0.75%
adenine and observed massive VC. Therefore, it is likely
that our protocol of adenine administration was insuffi-
cient to provoke the expected VC. In relation to 5/6Nx,
other studies employing this model have shown that, in
nephrectomized rats, VC is not detected through von
Kossa staining in normal conditions [3]. Therefore, it is
understandable that the von Kossa staining was negative
in the 5/6Nx group rats, since our study had a duration
time of 9 weeks. Another question is why the 5/6Nx
group rats presented higher calcium concentration in the
abdominal aorta than did the AIRF group rats. One hy-
pothesis is that the duration of CKD could be different in
the two models. Another possibility is that the high blood
pressure in 5/6Nx model could lead to a higher calcium
deposition. Therefore, if one plans to evaluate massive
VC, experimental animals must be fed higher concen-
trated adenine-diet for a longer period of time or must be
observed after several months in the 5/6Nx model [25].
Our study presents several limitations: we did not
measure biochemical variables or performed histomor-
phometric analysis at intermediate time points; we did
not evaluate different concentrations of adenine in the
diet; we could not separate the effects of PTH, FGF-23
or calcitriol, or kidney function in each of these models.
In addition, the duration of our experiment mimics ap-
proximately 4–5 years in human disease and it is known
that CKD-MBD has an insidious course of many years.
However, we were able to demonstrate for the first time
in a head-to-head comparison, that animals present dif-
ferent forms of CKD depending on the model that is
chosen. In face of our results, 5/6 Nx model should be
employed to study the effects of intervention on blood
pressure, on kidney disease progression, on serum levels
of PTH, FGF-23 and calcitriol or on mild bone lesions
of secondary hyperparathyroidism. It should also be used
in studies with longer observation period. On the other
hand, AIRF model should be used to evaluate ventricular
hypertrophy not related to hypertension or volume over-
load. The direct effect of adenine crystals on renal tubules
and interstitium impairs its use on studies of effects of
CKD-MBD therapy on CKD progression. Long term stud-
ies are also difficult with this model because there is a pro-
gressive undernutrition and severe renal disease, unless
lower concentrations of adenine are employed.
Conclusion
In summary, our study shows the peculiarities of the
adenine and 5/6Nx models in terms of the CKD-MBD
induced. Its main strength is that, for the first time, 5/6Nx
and adenine models were compared under similar condi-
tions of housing, feeding, and observation period. Using
the same experimental protocol for both models, we found
that the adenine model provokes massive phosphaturia
and a more severe form of bone disease, although we ob-
served no significant differences between the two models
in terms of VC. Nevertheless, the differences identified
should be taken into account when a specific model is
selected in order to evaluate the effects of CKD-MBD
therapies.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GOF: performed the experiments, analyzed the data, wrote the manuscript;
JCF: performed the experiments; RTC: performed the experiments; KRN:
conceived and designed the experiments, performed the experiments; LMR:
performed the experiments; WVD: performed the experiments; ECO: performed
the experiments; FGG: performed the experiments; JPD: conceived and designed
the experiments, VJ: conceived and designed the experiments; RMAM: conceived
and designed the experiments, performed the experiments, analyzed the data,
wrote the manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors are grateful for the assistance provided by Jefferson D. Boyles in
the translation and editing of the text, as well as for the technical assistance
provided by Rosimeire A. Bezerra Costa, Grasiela Pedreira Barlette, and Cássia
Macedo Pucci.
Funding
This study was supported by Fresenius Medical Care Deutschland GmbH,
Germany and Fapesp (grant 2008/53147-0). RMAM is supported by CNPQ,
Conselho Nacional de Desenvolvimento Científico e Tecnológico (grant
303325/2010-0). It was presented in part at the ASN Kidney Week 2011.
Author details
1Nephrology Department, Universidade de São Paulo, Rua Iperoig, 690, apto
121, São Paulo, Brazil. 2Division of Nephrology, University of Dusseldorf,
Dusseldorf, Germany.
Received: 10 December 2013 Accepted: 30 April 2014
Published: 3 May 2014
References
1. Kidney Disease: Improving global outcomes (KDIGO) CKD-MBD work
group KDIGO clinical practice guideline for the diagnosis, evaluation,
prevention, and treatment of chronic kidney disease-mineral and bone
disorder (CKD-MBD). Kidney Int Suppl 2009, 113:S1–S130.
2. Chauntin A, Ferris EB: Experimental renal insufficiency produced by
partial nephrectomy. Arch Intern Med 1932, 49:767–787.
Ferrari et al. BMC Nephrology 2014, 15:69 Page 6 of 7
http://www.biomedcentral.com/1471-2369/15/69
3. Shobeiri N, Adams MA, Holden RM: Vascular calcification in animal models
of CKD: a review. Am J Nephrol 2010, 31:471–481.
4. Yokozawa T, Oura T, Okada T: Metabolic effects of dietary purine in rats.
J Nutr Sci Vitaminol 1982, 28:519–526.
5. Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK,
Fukushima N: Sevelamer hydrochloride prevents ectopic calcification
and renal osteodystrophy in chronic renal failure rats. Kidney Int
2003, 64:441–450.
6. Tamagaki K, Yuan Q, Ohkawa H, Imazeki I, Moriguchi Y, Imai N, Sasaki S,
Takeda K, Fukagawa M: Severe Hyperparathyroidism with bone abnormalities
and metastatic calcifications in rats with adenine-induced uraemia. Nephrol
Dial Transplant 2006, 21:651–659.
7. Nagano N, Myata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M:
Effect of manipulating serum phosphorus with phosphate binder on
circulating PTH and FGF23 in renal failure rats. Kidney Int 2006,
69:531–537.
8. Gouveia CH, Jorgetti V, Bianco AC: Effects of thyroid hormone administration
and estrogen deficiency on bone mass of female rats. J Bone Miner Res 1997,
12:2098–2107.
9. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S,
Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification
of renal osteodystrophy: a position statement from Kidney Disease:
Improving Global Outcomes (KDIGO). Kidney Int 2006, 69:1945–1953.
10. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Maluche H,
Meunier PJ, Ott SM, Recker RR, Parfitt AM: Standardized symbols, and units
for bone histomorphometry: a 2012 update of the report of the ASBMR
Histomorphometry Nomenclature Committee. J Bone Miner Res 2013,
28:2–17.
11. Gagnon RF, Duguid WP: A reproducible model for chronic renal failure in
the mouse. Urol Res 1983, 11:11–14.
12. Terai K, Mizukami K, Okada M: Comparison of chronic renal failure rats
and modification of the preparation protocol as a hyperphosphataemia
model. Nephrology 2008, 13:139–146.
13. Oste L, Behets G, Dams G, Bervoets AR, Marynissen RL, Geryl H, van Hoof VO,
de Broe ME, D’Haese PC: Role of dietary phosphorus and degree of
uremia in the development of renal bone disease in rats. Ren Fail
2007, 29:1–12.
14. Nagano N, Myiata S, Obana S, Kobayashi N, Abe M, Fukushima N, Wada M:
Sevelamer hydrochloride, a calcium free phosphate binder, inhibits
parathyroid cell proliferation in partially nephrectomized rats. Nephrol
Dial Transplant 2003, 18(3):81–85.
15. Jokihaara J, Porsti IH, Koobi P, Jolma PM, Mustonem JT, Saha HH,
Sievanen H, Kannus P, Iwaniec UT, Turner RT, Jarvinen TL: Treatment
of experimental renal osteodystrophy with pamidronate. Kidney Int
2008, 74:319–327.
16. Graciolli FG, Neves KR, dos Reis LM, Graciolli RG, Noronha IL, Moysés RM,
Jorgetti V: Phosphorus overload and PTH induce aortic expression
of Runx2 in experimental uraemia. Nephrol Dial Transplant 2009,
24(5):1416–1421.
17. Damment S, Secker R, Shen V, Lorenzo V, Rodriguez M: Long-term
treatment with lanthanum carbonate reduces mineral and bone
abnormalities in rats with chronic renal failure. Nephrol Dial Transplant
2011, 26:1803–1812.
18. Neven E, Dams G, Postnov A, Postnov A, Chen B, de Clerck N, de Bro ME,
D’Haese PC, Persy V: Adequate phosphate binding with lanthanum
carbonate attenuates arterial calcification in chronic renal failure rats.
Nephrol Diet Transplant 2009, 14:1–10.
19. Moe S, Chen N, Seifert MF, Sinders RM, Duan D, Chen X, Liang Y, Radcliff JS,
White KE, Gattone VH 2nd: A rat model of chronic kidney disease-mineral
bone disorder. Kidney Int 2009, 75:176–184.
20. Ali BH, Ziada A, Al Husseni I, Beegam S, Nemmar A: Motor and behavioral
changes in rats with adenine-induced chronic renal failure: influence of
acacia gum treatment. Exp Biol Med 2011, 236(1):107–112.
21. Okabe C, Borges RL, de Almeida DC, Fanelli C, Barlette GP, Machado FG,
Arias SC, Malheiros DM, Camara NO, Zatz R, Fujihara CK: NF-κB activation
mediates crystal translocation and interstitial inflammation in
adenine overload nephropathy. Am J Physiol Renal Physiol 2013,
15(305(2)):F155–F163.
22. Sabbagh Y, Graciolli FG, O’Brien S, Tang W, dos Reis LM, Ryan S, Phillips L,
Boulanger J, Song W, Bracken C, Liu S, Ledbetter S, Dechow P, Canziani ME,
Carvalho AB, Jorgetti V, Moyses RM, Schiavi SC: Repression of osteocyte
Wnt/β-catenin signaling is an early event in the progression of renal
osteodystrophy. J Bone Miner Res 2012, 27(8):1757–1772.
23. Stubbs JR, He N, Idiculla A, Gilihan R, Liu S, David V, Hong Y, Quarles LD:
Longitudinal evaluation of FGF23 changes and mineral metabolism
abnormalities in a mouse model of chronic kidney disease. J Bone Miner
Res 2012, 27(1):38–46.
24. Orris I, Burnstock G, Arnett T: Purinergic signaling and bone remodeling.
Curr Opin Pharmacol 2010, 10(3):322–330.
25. Cozzolino M, Staniforth M, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E:
Sevelamer Hydrochloride attenuates kidney and cardiovascular calcifications
in long-term experimental uremia. Kidney Int 2003, 64:1653–1661.
doi:10.1186/1471-2369-15-69
Cite this article as: Ferrari et al.: Mineral bone disorder in chronic kidney
disease: head-to-head comparison of the 5/6 nephrectomy and adenine
models. BMC Nephrology 2014 15:69.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ferrari et al. BMC Nephrology 2014, 15:69 Page 7 of 7
http://www.biomedcentral.com/1471-2369/15/69
